Breast Cancer Clinical Trials in Maryland

Showing 561-580 of 799 trials

Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer

NCT01014715

The purpose of this study is to examine the feasibility to deliver PBI before the lumpectomy is performed. By administering the PBI before the lumpectomy, a smaller volume of breast tissue may be exposed to radiation. The PBI method used in this study is 3D (three dimensional) conformal external beam irradiation. 3D-conformal external beam irradiation uses an x-ray beam to deliver the radiation dose. Approximately 3 weeks after completion of the PBI, the cancer will be surgically removed. This study will learn about the good and bad effects of 3D-conformal external beam irradiation PBI when given before the cancer has been removed by lumpectomy. The study will also learn about the feelings women have about how their breast looks after PBI and surgery.

Breast Cancer

University of Maryland, Baltimore32 participantsStarted Sep 2009

Baltimore, Maryland, United States • Columbia, Maryland, United States • Glen Burnie, Maryland, United States

COMPLETEDPhase 212 miles

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

NCT00394082

The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.

Metastatic Breast Cancer

Celgene50 participantsStarted Jun 2006

Melbourne, Florida, United States • Ocoee, Florida, United States • Niles, Illinois, United States +17 more locations

Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Breast Cancer Trials in Other Cities

Mithramycin for Lung, Esophagus, and Other Chest Cancers

Testing a Spanish Version of a Patient Toxicity Questionnaire

Methods in Education for Breast Cancer Genetics

Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)

Lapatinib and Trastuzumab With or Without Endocrine Therapy

MRI to Detect Breast Tumors in Women

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Other Conditions in Maryland